Ovarian Cancer (Malignant Neoplasm) C&P Exam Prep

Hemoglobin (HGB) and Hematocrit (HCT)

What it measures: Blood oxygen-carrying capacity; used to assess anemia caused by cancer, cancer treatment (chemotherapy/radiation), or related bleeding. Critical for rating anemia as a secondary condition.

What to expect: The examiner will review recent laboratory results or may order a blood draw. Bring copies of your most recent CBC (complete blood count) results from your treating oncologist or primary care provider.

Pain considerations: Severe anemia from chemotherapy can cause debilitating fatigue and weakness that independently limits functioning - describe this as a distinct symptom cluster separate from cancer pain.

Pain Severity Assessment (Mild / Moderate / Severe)

What it measures: The examiner will determine whether the veteran experiences mild, moderate, or severe pain associated with ovarian cancer or its treatment. Under DC 7632 and 38 CFR 4.116, pain level is a direct rating factor for malignant neoplasms.

What to expect: The examiner will ask you to characterize your pain using a 0-10 scale and will categorize it as mild, moderate, or severe. They will also document frequency. Be prepared to describe pain on your worst days, not just an average day.

Pain considerations: Pain from ovarian cancer can be multifactorial: tumor pressure, post-surgical adhesions, peripheral neuropathy from platinum-based chemotherapy, and bone pain from metastases or hormonal changes. Each type should be described separately to the examiner.

Incontinence / Absorbent Material Assessment

What it measures: The examiner documents whether urinary or fecal incontinence is present and the severity as measured by the number of absorbent pad changes required per day. This affects rating for urinary or fecal incontinence as residuals of ovarian cancer treatment.

What to expect: The examiner will ask whether you experience incontinence, whether you use absorbent pads or diapers, and how many times per day you change them. They may also ask about fistulas (abnormal connections between urinary/bowel tract and vagina).

Pain considerations: Incontinence can cause significant social isolation, embarrassment, and psychological distress - communicate the full functional and social impact to the examiner, not just the number of pad changes.

100%

Active malignancy, or during and following treatment with antineoplastic chemotherapy, radiation therapy, or surgery. Under 38 CFR 4.29 and 4.30, a temporary 100% rating is assigned during active treatment and is continued for a specified period following treatment completion. Additionally, a 100% rating applies when symptoms are not controlled despite continuous treatment, or when the condition results in severe systemic involvement (e.g., widespread metastases, severe pain, severe constitutional symptoms).

From 38 CFR: Under 38 CFR 4.116 (DC 7632) and the provisions of 38 CFR 4.29/4.30, a veteran with active ovarian cancer or undergoing antineoplastic therapy receives a 100% rating. This rating continues for a mandatory evaluation period (typically 6 months) after treatment completion, after which the condition is re-evaluated for residuals.

100%

Post-treatment 100% rating continuation: Following completion of antineoplastic therapy (chemotherapy, radiation, or surgery), the 100% rating is continued for a mandatory minimum period per 38 CFR 4.29 (chemotherapy/radiation: 6 months post-completion) and 38 CFR 4.30 (surgery). After this period, the condition is re-evaluated based on residuals. Veterans should be aware that VA will schedule a future examination approximately 6 months after treatment ends.

From 38 CFR: 38 CFR 4.29 mandates a minimum 6-month continuation of the 100% rating following completion of chemotherapy or radiation therapy. 38 CFR 4.30 provides similar protections following surgery. The veteran should not be reduced below 100% during this mandatory continuation period.

30%

Following the mandatory post-treatment continuation period, if the cancer is in complete remission with no evidence of disease (NED), the rating is evaluated based on residuals under the appropriate diagnostic code(s). A minimum 30% rating may apply based on documented residuals such as surgical removal of an ovary (oophorectomy), peripheral neuropathy from chemotherapy, lymphedema, bowel/bladder dysfunction, fatigue, hormonal changes from surgical menopause, or other lasting complications. Each residual may be separately rated.

From 38 CFR: Under 38 CFR 4.116, after the mandatory continuation period, residuals of ovarian cancer and its treatment are rated under the most analogous diagnostic code(s). For example: complete oophorectomy (DC 7619 - 30%), peripheral neuropathy (DC 8620/8720 series), incontinence, or other organ-specific residuals. Each ratable residual should be separately claimed and evaluated.

Pain (Pelvic, Abdominal, Neuropathic)

How to describe it: Describe all pain associated with ovarian cancer and its treatment. Separate tumor-related pain from surgical pain from neuropathic pain (burning/tingling in hands and feet from chemotherapy). Rate each on a 0-10 scale and describe frequency (constant, daily, several times per week), location, and what makes it better or worse. Use specific activity limitations to illustrate severity.

Example: On my worst days - which happen several times a week - I have severe pelvic pressure and deep abdominal pain that rates 8 out of 10. I cannot sit for more than 20 minutes, I cannot do household tasks, and I have to lie down for hours. Additionally, my feet burn and feel numb from chemotherapy neuropathy, making it painful to walk more than half a block.

Examiner listens for: Differentiation between mild, moderate, and severe pain; frequency of severe episodes; functional limitations caused by pain; whether pain is controlled by current medications or uncontrolled despite treatment; impact on sleep, work, and daily activities.

Avoid: Do not say 'my pain is manageable' without clarifying that it requires heavy pain medication to achieve that level. Do not describe only your good days - M21-1 instructs examiners to rate based on the full picture including worst-day functioning.

Treatment Status and Ongoing Therapy

How to describe it: Clearly state whether you are currently in active treatment (chemotherapy, radiation, targeted therapy, immunotherapy, maintenance therapy such as PARP inhibitors or bevacizumab), have recently completed treatment, or are in surveillance/remission. Know your exact treatment dates, facilities, and drug regimens if possible. The examiner will ask whether treatment is completed or ongoing.

Example: I completed my sixth cycle of carboplatin and paclitaxel chemotherapy on [date] at [facility]. I am currently on maintenance olaparib (PARP inhibitor). During active chemotherapy, I was completely disabled - I could not leave my home for weeks at a time, required assistance with personal care, and was hospitalized twice for neutropenic fever.

Examiner listens for: Specific treatment modalities, dates of initiation and completion, whether treatment is completed or ongoing, whether there is evidence of recurrence requiring additional treatment, and the severity of treatment-related side effects.

Avoid: Do not minimize the severity of chemotherapy side effects as 'just the typical side effects.' Document each side effect that limits your functioning. Do not forget to mention maintenance therapy - being on maintenance PARP inhibitors or bevacizumab means treatment is NOT completed.

Cancer Status (Active vs. Remission) and Recurrence

How to describe it: Be precise about your current disease status as documented in your medical records. Active disease, partial response to treatment, complete clinical response, NED (no evidence of disease), or recurrence after remission all carry different rating implications. If you have had a recurrence, describe when it was detected, how, and what treatment followed.

Example: My oncologist confirmed complete clinical remission following surgery and chemotherapy, but my CA-125 levels began rising again at my 18-month surveillance visit, and a PET scan showed recurrent peritoneal disease. I am now back on active chemotherapy for my second recurrence.

Examiner listens for: Whether the cancer is primary or metastatic, the current disease status at the time of examination, history of recurrences, whether surveillance is ongoing, and the most recent imaging or tumor marker results.

Avoid: Do not assume the examiner has reviewed all your oncology records. Bring copies of your most recent imaging reports, CA-125 trending results, and oncology notes to clearly establish current disease status.

Residuals After Treatment - Physical

How to describe it: Comprehensively describe every lasting physical effect of both the cancer and its treatment. These residuals are separately ratable conditions. Common residuals include: peripheral neuropathy, lymphedema, surgical menopause symptoms, bowel dysfunction, bladder dysfunction (urgency, incontinence), abdominal adhesions, fatigue, and changes in body composition.

Example: Since completing treatment, I have permanent numbness and burning in both feet from chemotherapy neuropathy - I fall frequently and cannot walk safely on uneven ground. I also experience severe hot flashes and night sweats from surgical menopause that disrupt my sleep every night, and I have urinary urgency incontinence requiring 3-4 pad changes per day due to radiation damage to my bladder.

Examiner listens for: Specific residual conditions that are separately diagnosable and ratable; impact on mobility, continence, sleep, and daily activities; whether residuals require ongoing treatment; objective findings on physical examination.

Avoid: Do not lump all residuals together as 'some side effects from chemo.' Name each residual specifically. Do not forget that surgical menopause resulting from bilateral oophorectomy is itself a separately ratable condition (DC 7619).

Functional and Occupational Impact

How to describe it: Describe in concrete terms how ovarian cancer and its treatment have affected your ability to work, perform household tasks, maintain relationships, exercise, and care for yourself. Use specific time-based examples and quantify limitations where possible (e.g., 'I can only stand for 10 minutes before pain forces me to sit,' or 'I missed 60 days of work during chemotherapy').

Example: During active treatment I was completely unable to work and required my spouse to assist me with bathing and meal preparation. Even now in remission, my neuropathy prevents me from performing the computer work my job requires, and my fatigue limits me to about 4 hours of productive activity per day before I must rest. I have not been able to return to full-time employment.

Examiner listens for: Specific occupational limitations, loss of income or employment, need for assistance with activities of daily living, impact on social and family functioning, use of assistive devices, and whether the veteran has been granted TDIU (total disability individual unemployability).

Avoid: Do not say 'I manage' without explaining the cost of that management (extra rest, medication, assistance from others, giving up activities). Do not assume functional limitations are obvious from a diagnosis alone - spell them out explicitly.

Incontinence and Absorbent Material Use

How to describe it: If you experience urinary or fecal incontinence from treatment (radiation damage, surgical damage, fistulas), describe the type, frequency, and severity. Be specific about the number of pads or absorbent products you use per day on your worst days. Note if you use any appliances such as a catheter, urostomy, or colostomy bag.

Example: On bad days - which happen at least three to four days per week - I experience urinary urgency incontinence and must change my absorbent pad five or more times. I have had two episodes of urethrovaginal fistula symptoms confirmed by my urologist as a consequence of pelvic radiation. This prevents me from leaving home for extended periods and causes me significant social embarrassment and isolation.

Examiner listens for: Whether incontinence is present, its cause (radiation, surgery, fistula), the number of pad changes per day on worst days, whether appliances are required, and the social and functional impact of incontinence.

Avoid: Do not underreport pad usage out of embarrassment. The number of pad changes is a direct rating criterion. Bring a note from your urologist or gynecologist documenting the diagnosis and treatment of incontinence if available.